# PeptideScanner evidence objects: Pemvidutide

Every published version of the records placed with Pemvidutide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json. Selected public evidence only; not medical advice.

- Objects: 6
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct04561245-pemvidutide-v1"></a>

## ClinicalTrials.gov record NCT04561245

> PeptideScanner retained ClinicalTrials.gov record NCT04561245 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-24, and PeptideScanner's reviewed identity mapping was pemvidutide.

- Evidence object: `story:clinicaltrials-gov-nct04561245-pemvidutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-06-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04561245-pemvidutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#clinicaltrials-gov-nct04561245-pemvidutide-v1
- Content SHA-256: `163d46048bc96469a6ea68cf66a030c1f2e9917d934ac88581f6b94abb4b3cd0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04561245 ([`ctg-observation-nct04561245-2025-06-24-1e6939e41736`](#source-ctg-observation-nct04561245-2025-06-24-1e6939e41736))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04561245 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-24, and PeptideScanner's reviewed identity mapping was pemvidutide. ([`ctg-observation-nct04561245-2025-06-24-1e6939e41736`](#source-ctg-observation-nct04561245-2025-06-24-1e6939e41736))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04561245 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-24, and PeptideScanner's reviewed identity mapping was pemvidutide. ([`ctg-observation-nct04561245-2025-06-24-1e6939e41736`](#source-ctg-observation-nct04561245-2025-06-24-1e6939e41736))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04561245-2025-06-24-1e6939e41736`](#source-ctg-observation-nct04561245-2025-06-24-1e6939e41736))

### Sources

<a id="source-ctg-observation-nct04561245-2025-06-24-1e6939e41736"></a>
- **ClinicalTrials.gov record NCT04561245 · retained source version 2025-06-24:1e6939e417365c1394244d943ca47339571423ba9976eb3f9522e85c0bff80da** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04561245) (`ctg-observation-nct04561245-2025-06-24-1e6939e41736`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04561245." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#clinicaltrials-gov-nct04561245-pemvidutide-v1 SHA-256: 163d46048bc96469a6ea68cf66a030c1f2e9917d934ac88581f6b94abb4b3cd0.

---

<a id="clinicaltrials-gov-nct05989711-pemvidutide-v1"></a>

## ClinicalTrials.gov record NCT05989711

> PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide.

- Evidence object: `story:clinicaltrials-gov-nct05989711-pemvidutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05989711-pemvidutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#clinicaltrials-gov-nct05989711-pemvidutide-v1
- Content SHA-256: `7990afbb4cafebf26f21df29337f833a76f50518f4a14e31a688bc33dfe65a68`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05989711 ([`ctg-observation-nct05989711-2026-05-18-f84dcb32254a`](#source-ctg-observation-nct05989711-2026-05-18-f84dcb32254a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide. ([`ctg-observation-nct05989711-2026-05-18-f84dcb32254a`](#source-ctg-observation-nct05989711-2026-05-18-f84dcb32254a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide. ([`ctg-observation-nct05989711-2026-05-18-f84dcb32254a`](#source-ctg-observation-nct05989711-2026-05-18-f84dcb32254a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05989711-2026-05-18-f84dcb32254a`](#source-ctg-observation-nct05989711-2026-05-18-f84dcb32254a))

### Sources

<a id="source-ctg-observation-nct05989711-2026-05-18-f84dcb32254a"></a>
- **ClinicalTrials.gov record NCT05989711 · retained source version 2026-05-18:f84dcb32254af97b66c990fff5134dc14f38c373692c50c6eeb0d5081ffdcdec** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05989711) (`ctg-observation-nct05989711-2026-05-18-f84dcb32254a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05989711." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#clinicaltrials-gov-nct05989711-pemvidutide-v1 SHA-256: 7990afbb4cafebf26f21df29337f833a76f50518f4a14e31a688bc33dfe65a68.

---

<a id="clinicaltrials-gov-nct06987513-pemvidutide-v1"></a>

## ClinicalTrials.gov record NCT06987513

> PeptideScanner retained ClinicalTrials.gov record NCT06987513 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was pemvidutide.

- Evidence object: `story:clinicaltrials-gov-nct06987513-pemvidutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-31
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06987513-pemvidutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#clinicaltrials-gov-nct06987513-pemvidutide-v1
- Content SHA-256: `57c828640925a1a62cf20e4414300392ec82a3d1207454c588758301c80cc612`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06987513 ([`ctg-observation-nct06987513-2026-07-31-1e0339600b69`](#source-ctg-observation-nct06987513-2026-07-31-1e0339600b69))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06987513 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was pemvidutide. ([`ctg-observation-nct06987513-2026-07-31-1e0339600b69`](#source-ctg-observation-nct06987513-2026-07-31-1e0339600b69))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06987513 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was pemvidutide. ([`ctg-observation-nct06987513-2026-07-31-1e0339600b69`](#source-ctg-observation-nct06987513-2026-07-31-1e0339600b69))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06987513-2026-07-31-1e0339600b69`](#source-ctg-observation-nct06987513-2026-07-31-1e0339600b69))

### Sources

<a id="source-ctg-observation-nct06987513-2026-07-31-1e0339600b69"></a>
- **ClinicalTrials.gov record NCT06987513 · retained source version 2026-07-31:1e0339600b69d593251060e3e950a1115e96aaa4c5a8b3ff662651ac4049cd93** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06987513) (`ctg-observation-nct06987513-2026-07-31-1e0339600b69`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06987513." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#clinicaltrials-gov-nct06987513-pemvidutide-v1 SHA-256: 57c828640925a1a62cf20e4414300392ec82a3d1207454c588758301c80cc612.

---

<a id="clinicaltrials-gov-nct07009860-pemvidutide-v1"></a>

## ClinicalTrials.gov record NCT07009860

> PeptideScanner retained ClinicalTrials.gov record NCT07009860 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was pemvidutide.

- Evidence object: `story:clinicaltrials-gov-nct07009860-pemvidutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07009860-pemvidutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#clinicaltrials-gov-nct07009860-pemvidutide-v1
- Content SHA-256: `38d69980b648df9308c48ac19c71b409ad61ff1bb36aac1352777d97289dd945`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07009860 ([`ctg-observation-nct07009860-2026-03-20-c02a1977625c`](#source-ctg-observation-nct07009860-2026-03-20-c02a1977625c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07009860 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was pemvidutide. ([`ctg-observation-nct07009860-2026-03-20-c02a1977625c`](#source-ctg-observation-nct07009860-2026-03-20-c02a1977625c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07009860 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was pemvidutide. ([`ctg-observation-nct07009860-2026-03-20-c02a1977625c`](#source-ctg-observation-nct07009860-2026-03-20-c02a1977625c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07009860-2026-03-20-c02a1977625c`](#source-ctg-observation-nct07009860-2026-03-20-c02a1977625c))

### Sources

<a id="source-ctg-observation-nct07009860-2026-03-20-c02a1977625c"></a>
- **ClinicalTrials.gov record NCT07009860 · retained source version 2026-03-20:c02a1977625c558c78b022bf4ffb2fb17b8f36e6d148e6e732dd570f2188541e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07009860) (`ctg-observation-nct07009860-2026-03-20-c02a1977625c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07009860." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#clinicaltrials-gov-nct07009860-pemvidutide-v1 SHA-256: 38d69980b648df9308c48ac19c71b409ad61ff1bb36aac1352777d97289dd945.

---

<a id="clinicaltrials-gov-nct07795164-pemvidutide-v1"></a>

## ClinicalTrials.gov record NCT07795164

> PeptideScanner retained ClinicalTrials.gov record NCT07795164 at 2026-09-09T19:17:17.076Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was pemvidutide.

- Evidence object: `story:clinicaltrials-gov-nct07795164-pemvidutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-31
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07795164-pemvidutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#clinicaltrials-gov-nct07795164-pemvidutide-v1
- Content SHA-256: `8533bc0a2a9906f61f15fda51ef6a3ce0d1c42d0ea2a7f9c48b7929485c6eec7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07795164 ([`ctg-observation-nct07795164-2026-08-31-445923515599`](#source-ctg-observation-nct07795164-2026-08-31-445923515599))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07795164 at 2026-09-09T19:17:17.076Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was pemvidutide. ([`ctg-observation-nct07795164-2026-08-31-445923515599`](#source-ctg-observation-nct07795164-2026-08-31-445923515599))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07795164 at 2026-09-09T19:17:17.076Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was pemvidutide. ([`ctg-observation-nct07795164-2026-08-31-445923515599`](#source-ctg-observation-nct07795164-2026-08-31-445923515599))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07795164-2026-08-31-445923515599`](#source-ctg-observation-nct07795164-2026-08-31-445923515599))

### Sources

<a id="source-ctg-observation-nct07795164-2026-08-31-445923515599"></a>
- **ClinicalTrials.gov record NCT07795164 · retained source version 2026-08-31:445923515599b1c75e5a12a2ec64209d4453be7d93d0614bca15d8035020d448** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07795164) (`ctg-observation-nct07795164-2026-08-31-445923515599`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07795164." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#clinicaltrials-gov-nct07795164-pemvidutide-v1 SHA-256: 8533bc0a2a9906f61f15fda51ef6a3ce0d1c42d0ea2a7f9c48b7929485c6eec7.

---

<a id="pemvidutide-impact-study-updated-v1"></a>

## Pemvidutide IMPACT study record updated

> ClinicalTrials.gov lists a completed Pemvidutide study sponsored by Altimmune, Inc.

- Evidence object: `story:pemvidutide-impact-study-updated:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-18
- Source checked: 2026-07-22
- Published by PeptideScanner: 2026-07-22
- Story landing page: https://peptidescanner.com/stories/pemvidutide-impact-study-updated/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#pemvidutide-impact-study-updated-v1
- Content SHA-256: `fa250900e58c9eed973640c966c07ee7043812e0f06166d6ea15cec2fae60d84`

### Claims and source pins

#### Headline

Pemvidutide IMPACT study record updated ([`ctg-nct05989711-v10`](#source-ctg-nct05989711-v10))

#### Summary

ClinicalTrials.gov lists a completed Pemvidutide study sponsored by Altimmune, Inc. ([`ctg-nct05989711-v10`](#source-ctg-nct05989711-v10))

#### Paragraph 1

ClinicalTrials.gov lists the NCT05989711 record under Altimmune, Inc. Its overall recruitment status was shown as completed when PeptideScanner reviewed the record. ([`ctg-nct05989711-v10`](#source-ctg-nct05989711-v10))

#### Paragraph 2

The registry shows 2026-05-18 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome. ([`ctg-nct05989711-v10`](#source-ctg-nct05989711-v10))

### Sources

<a id="source-ctg-nct05989711-v10"></a>
- **IMPACT: Pemvidutide in Participants With NASH · record history version 10 · last update posted 2026-05-18** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05989711?a=10&tab=history) (`ctg-nct05989711-v10`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pemvidutide IMPACT study record updated." Version 1, published 2026-07-22. https://peptidescanner.com/evidence/v1/peptides/pemvidutide.json#pemvidutide-impact-study-updated-v1 SHA-256: fa250900e58c9eed973640c966c07ee7043812e0f06166d6ea15cec2fae60d84.

